Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus placebo in active ankylosing spondylitis (phase III, subcutaneous, 16-week efficacy and 52-week safety)
2015-005021-39Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Secukinumab 150 mg subcutaneous with Placebo subcutaneous (2 arms). Primary endpoint: ASAS20 response at week 16. Started Jul 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2015-005021-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005021-39.